Skip to content

Axial Involvement in Psoriatic Arthritis LUMC

Axial Involvement in Psoriatic Arthritis LUMC - AXIS-LUMC

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON53984
Enrollment
20
Registered
2023-09-04
Start date
2023-11-01
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psoriatic arthritis

Interventions

None listed

Sponsors

Leids Universitair Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1) Age >= 18 years. 2) Definite diagnosis of PsA. 3) Fulfilment of the CASPAR criteria for PsA. 4) Duration of PsA symptoms

Exclusion criteria

Exclusion criteria: 1) Unable or unwilling to give informed consent or to comply with the protocol. 2) Current or past treatment with biologic or a targeted synthetic disease-modifying antirheumatic drug (DMARDs). 3) Contraindications for MRI and/or plain radiograph examination of sacroiliac joints and spine.

Design outcomes

Primary

MeasureTime frame
The frequency of axial involvement in patients with psoriatic arthritis will be expressed as an absolute number and as a percentage based on both local and central assessment. The burden can be considered to be very low. Information is obtained from patient records or the treating physician at baseline. Patients receive usual care and they will not receive any intervention. Since the nature of this study is observational, and the burden on the participants is very low, there will not be any risks in taking part in this study

Secondary

MeasureTime frame
Frequency of active inflammatory and structural changes on imaging suggestive of inflammatory involvement of axial skeleton (sacroiliac joints and spine) in psoriatic arthritis will be expressed an absolute number and as a percentage;

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)